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Genetic diseaseMitochondrial respiratory chain deﬁciencies represent one of the major causes of metabolic disorders that are
related to genetic defects in mitochondrial or nuclear DNA. The mitochondrial protein synthesis allows the
synthesis of the 13 respiratory chain subunits encoded bymtDNA. Altogether, about 100 different proteins are
involved in the translation of the 13 proteins encoded by the mitochondrial genome emphasizing the
considerable investment required to maintain mitochondrial genetic system. Mitochondrial protein synthesis
deﬁciency can be caused by mutations in any component of the translation apparatus including tRNA, rRNA
and proteins. Mutations in mitochondrial rRNA and tRNAs have been ﬁrst identiﬁed in various forms of
mitochondrial disorders. Moreover abnormal translation due to mutation in nuclear genes encoding tRNA-
modifying enzymes, ribosomal proteins, aminoacyl-tRNA synthetases, elongation and termination factors and
translational activators have been successively described. These deﬁciencies are characterized by a huge
clinical and genetic heterogeneity hampering to establish genotype–phenotype correlations and an easy
diagnosis. One can hypothesize that a new technique for gene identiﬁcation, such as exome sequencing will
rapidly allow to expand the list of genes involved in abnormal mitochondrial protein synthesis.LSFC, Leigh Syndrome French
ctic acidosis and sideroblastic
mitochondrial; mtDNA, mito-
; PEO, progressive external
al RNA; SNHL, sensorineural
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Oxidative phosphorylation (OXPHOS), i.e., ATP synthesis and the
oxygen-consuming respiratory chain (RC), supplies most organs and
tissueswith a readily utilizable energy source, being already functional
before birth. Consequently, OXPHOS deﬁciency can theoretically give
rise to any symptom, in any organ or tissue, at any age, with anymode
of inheritance, due to the twofold genetic origin of OXPHOS
components (nuclear DNA and mitochondrial DNA). Mitochondrial
OXPHOS deﬁciencies represent one of the major causes of metabolic
disorders with a prevalence estimated at 1/8500 birth [10]. These
disorders represent a heterogeneous group of genetic diseases and can
be caused by genetic defects in mitochondrial or nuclear DNA. This
review will focus on mitochondrial diseases related to impaired
translation of the 13 proteins encoded by the mitochondrial DNA.
1.1. The mitochondrial respiratory chain
The mitochondrial OXPHOS catalyzes the oxidation of fuel
molecules by oxygen and the concomitant energy transduction intoATP via ﬁve complexes, embedded in the inner mitochondrial
membrane [19]. Complex I (NADH–coenzyme Q reductase) carries
reducing equivalents from NADH to coenzyme Q (CoQ, ubiquinone)
and consists of more than 40 different polypeptides. Complex II
(succinate–CoQ reductase) carries reducing equivalents from FADH2
to CoQ and contains 4 polypeptides, including the FAD-dependent
succinate dehydrogenase and iron–sulfur proteins. Complex III
(reduced CoQ–cytochrome c reductase) carries electrons from CoQ
to cytochrome c. It contains 11 subunits. Complex IV (cytochrome c
oxidase, COX), the terminal oxidase of the RC, catalyzes the transfer of
reducing equivalents from cytochrome c to molecular oxygen. It is
composed of 2 cytochromes (a and a3), 2 copper atoms and 13
different protein subunits.
The mitochondrial OXPHOS is made up of about 100 different
proteins. Only 13 of them are encoded bymitochondrial genes and the
others by nuclear genes. All complexes of the OXPHOS, except
complex II have a double genetic origin. Indeed, 1 to 7 subunits of
these complexes are mitochondrially encoded. Moreover, it is
hypothesized that several hundreds of nuclear genes are also needed
for various functions of the OXPHOS. Therefore, the number of
mitochondrial proteins represents more than 3% of all the cellular
proteins.
1.2. The mitochondrial DNA
The human mitochondrial DNA (mtDNA) is a 16,569 base pair
double stranded circular molecule. Mitochondrion makes a large
reticular network and contains several molecules of mtDNA. This
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coding region, the displacement or D-loop which contains the
promoters for transcription initiation. This genome is present at
hundreds to thousands of copies per cell. This molecule contains 13
genes for key OXPHOS subunits. ND1–ND6 are subunits of complex I,
cytochrome b (cytb) is the only mitochondrially encoded subunit of
complex III, COXI–COXIII are subunits of complex IV and ATP6, ATP8 of
ATP synthase (complex V). Moreover, mtDNA encodes a large and a
small ribosomal RNA (12S rRNA and 16S rRNA) and 22 transfer RNAs
(tRNA) scattered along the entire molecule.
The mitochondrion has independent replication, transcription and
translation systems. The mitochondrial genome is replicated in two
times. The replication starts at the heavy strand replication origin
(OH) and extends clockwise around the mtDNA. When the light
strand replication origin (OL) is exposed as a single strand, the second
strand is then replicated in the opposite direction, starting from OL
[11]. Thus, replication is bi-directional but asynchronous. Recently, a
newmodel of mtDNA replication has been proposed in mammals. The
mtDNA replication arises from multiple origins and proceeds by a
strand-coupled mechanism [58]. The two mtDNA strands are
transcribed from speciﬁc promoters into polycistronic RNAs, which
are further, processed into ribosomal RNAs (rRNA), transfer RNAs
(tRNA) and messenger RNAs (mRNA). The mitochondrial mRNAs are
translated in the mitochondrial matrix using nuclearly encoded
machinery, but following a speciﬁc genetic code, different from the
nuclear one.
During cell division, mitochondria are randomly partitioned in
daughter cells (mitotic segregation). Usually all the mtDNAmolecules
are identical, but sometimes a mixture of wild type and mutant
mtDNA is encountered. This situation is called heteroplasmy, whereas
homoplasmy refers to the occurrence of only one type of mtDNA. In
heteroplasmic cells, the mtDNA genotype can shift during cell
replication. Consequently, some lineages drift toward wild-
type mtDNA and become homoplasmic, while others remain
heteroplasmic.
The mitochondrial genome is maternally transmitted. The mother
transmits her mtDNA to all her progeny, males and females, and her
daughters transmit their mtDNA to the next generation. Theoretically,
males never transmit their mtDNA.
1.3. The nuclear genes
The majority of mitochondrial proteins are encoded by nuclear
genes. Mitochondria contain around 1100–1400 proteins [8] and
several hundreds of them are related to RC. These genes encode
subunits of the RC, proteins involved in the assembly of the OXPHOS
complexes, in synthesis of cofactors, in mtDNA metabolism and
maintenance (mtDNA replication, transcription, repair, and dNTP
synthesis), in translation of the 13 OXPHOS subunits of mitochondrial
origin.
2. The mitochondrial protein synthesis
Themitochondrial mRNA translation allows the synthesis of the 13
OXPHOS subunits encoded by mtDNA. The mammalian mitochondrial
protein synthesis apparatus is not completely known. It resembles its
prokaryotic counterpart but obviously presents speciﬁc characteris-
tics. It is also different from the cytosolic translation machinery and
apart few rare examples has a speciﬁc machinery.
Themitochondrial genetic code shows several differences from the
universal code. AUA codes for methionine and not for isoleucine. UAG
is used as stop codon. Finally, UGA serves as codon for tryptophan
rather than a stop codon. The mammalian mtDNA contains only 22
tRNA genes that are sufﬁcient to read all codons with a mechanism
unique to mitochondrial system. The mitochondrial mRNAs containvery few nucleotide in the 5′-end untranslated (UTR) regions and cap
structure.
The proteins encoded by mtDNA are all hydrophobic proteins
located in the inner mitochondrial membrane. Mitochondrial mRNA
translation has been suggested to take place in a complex bound to
the inner membrane through electrostatic force and may also be
through protein interaction [27]. At least one inner membrane
protein, LETM1, has been suggested to serve as an anchor protein
for complex formation with the mitochondrial ribosome [32]. This
protein seems also to be involved in Ca2+ transport [54]. Yeast Oxa1
protein, which facilitates the cotranslational insertion of the nascent
polypeptide chains into the mitochondrial inner membrane, is closely
associated to the large ribosomal subunit protein, MrpL40 [22]. It
should also be mentioned that translational activator proteins in yeast
are integral membrane proteins or bound to the mitochondrial inner
membrane.
Themitochondrial ribosomal and transfert RNAs (rRNAs and tRNAs)
are encoded bymtDNA but all proteins of the translationmachinery are
encoded bynuclear genes. Themitochondrial protein synthesis requires
ribosomal proteins, ribosomal assembly proteins, aminoacyl-tRNA
synthetases, tRNA-modifying enzymes, rRNA methylating enzymes
such as TFB1M and several initiation, elongation and termination
translation factors. Altogether, about 150 different proteins are involved
in the translation of the 13 proteins encoded by the mitochondrial
genome emphasizing the considerable investment required tomaintain
a mitochondrial genetic system.
3. Protein synthesis deﬁciencies in human
Protein synthesis deﬁciency can be caused by mutations in any
component of the translation apparatus including tRNA, rRNA and
proteins. It can therefore present any mode of inheritance. Until now
only maternal and autosomal recessive transmission of these
deﬁciencies has been observed. These protein synthesis anomalies
result in OXPHOS deﬁciency affecting theoretically all complexes
containing mitochondrially encoded subunits sparing complex II. The
aim of this review is to describe the various molecular mechanisms of
protein synthesis deﬁciencies in human. For reviews onmitochondrial
protein synthesis in mammals see Refs. [45,49].
3.1. Mitochondrial tRNA mutations
The ﬁrst mutations affecting mitochondrial mRNA translation were
described 20 years ago. The A3243G mutation in the tRNALeu(UUR)
(MTTL1) gene is responsible for mitochondrial encephalomyopathy
with lactic acidosis and stroke-like episodes (MELAS) syndrome [17].
MELAS is characterized by onset in childhood with intermittent
hemicranial headache, vomiting, proximal limb weakness, and recur-
rent neurological deﬁcit resembling strokes (hemiparesis, cortical
blindness, hemianopsia), lactic acidosis and occasionally ragged red
ﬁbers in the muscle biopsy. CT brain scan shows low-density areas
(usually posterior) which may affect both white and gray matter but
does not always correlate to clinical symptoms or vascular territories
The pathogenesis of stroke-like episodes in MELAS has been ascribed to
either cerebral blood ﬂow disruption or acute metabolic decompensa-
tion in biochemically deﬁcient areas of the brain. Additional mutations
in this gene have been reported in association with MELAS or MELAS/
myopathy syndrome [38]. This gene is a hotspot for pathogenic
mutations.
In the following years more than 150 mutations in tRNAs have
been described in association with various clinical presentations
(encephalopathy, encephalomyopathy, Leigh syndrome, myopathy,
chronic progressive external ophthalmoplegia, Fig. 1). One of the
most common is the A8344G missense mutation in the mt tRNALys
gene that accounts for 80% of Myoclonus Epilepsy with Ragged Red
Fibers (MERRF) cases [44]. This disease is characterized by an
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weakness and generalized seizures. The tRNAIle gene is the third
most commonly mutated tRNA gene. Different mutations of this
gene are associatedwith cardiomyopathy and PEO. Thesemutations
are usually heteroplasmic and maternally inherited. Some of the
tRNA gene mutations are restricted to only one family and the
pathogenicity of all these mutations has not been always estab-
lished. The tRNALeu(UUR), tRNALys, and tRNAIle mutations represent
almost half of the known mutations associated with deﬁnite and
probable pathogenicity [41].
Theeffect of thesemutations onprotein synthesis is of variablenature.
The 3243ANGMELASmutation affects the stability of tRNALeu(UUR) [5]. It
also prevents taurine modiﬁcation in the anticodon. Finally it has been
demonstrated that this mutation decreases the stability of themitochon-
drial translationproducts and induces amino acidmisincorporation in the
mitochondrial translation product demonstrating that the A3243G
mutation produces both loss- and gain-of-function phenotypes [40].3.2. Mitochondrial rRNA mutations
Ribosomal RNA (rRNA)mutations are associatedwith aminoglyco-
side-induced deafness. The A1555G mutation in the 12S rRNA gene
was ﬁrst described in a large Arab–Israeli pedigree [34] and
subsequently found in many families of various ethnic backgrounds
[56]. The incidence of the A1555G mutation varies from 0.6 to 2.5% of
the Caucasian clinical population but is higher in Asia (2.9% in China,
3% in Japan, and 5.3% in Indonesia). Surprisingly, 17% of Spanish
population with postlingual non-syndromic hearing loss carried this
mutation. Usually, the A1555G mutation occurs in homoplasmy, but
in some families the heteroplasmic state was identiﬁed [14].
Sensorineural hearing loss (SNHL) for this mutation may be triggered
by the use of aminoglycosides, and may also occur without exposure
to these drugs [53]. In the absence of aminoglycosides, the A1555G
mutation produces a variable clinical phenotype among family
members [34]. Also, the penetrance differs between families for this
mutation. In some pedigrees, most of the individuals carrying the
A1555G mutation subsequently develop SNHL, but, in others, the
penetrance may be extremely low [56]. These ﬁndings indicate that
the A1555G mutation itself is not sufﬁcient to produce a clinical
phenotype but requires the involvement of modiﬁer factors for the
phenotypic expression.Fig. 1. Mitochondrial DNA strucutre and tRNA mutations. The letters indicate the
various tRNA and the numbers between brackets the number of different mutations of
each tRNA according to Ref. [38].3.3. Messenger RNA stability
After processing of the polycistronic RNAs, mRNAs are oligo or
polyadenylated at the 3′ termini. This polyadenylation is crucial not
only for maintaining global mRNA steady-state levels but also allows
to optimize mitochondrial protein synthesis. A homozygous mutation
in MTPAP gene, encoding the poly(A) RNA polymerase was identiﬁed
in an Amish family with spastic ataxia that resulted in severely
truncated poly(A) tails [13].
3.4. Abnormal tRNA modiﬁcation
The maturation of transfer RNA (tRNA) involves a number of
nucleoside modiﬁcations necessary for their proper physiological
functioning. This inﬂuences both their structural and functional
properties, including structure stabilization, amino-acylation and
codon recognition. For example, the folding of tRNALys into cloverleaf
structure and aminoacylation of tRNAIle are dependant of speciﬁc base
modiﬁcations of the tRNAs [20]. In mammalian mitochondrial tRNAs
one nucleotide in 17–18 is modiﬁed [20]. Several mitochondrial tRNA
modiﬁcations have been identiﬁed in human but the proteins
involved in these modiﬁcations are far from being all identiﬁed.
PUS1 encodes a pseudouridine synthase that converts uridine into
pseudouridine after the nucleotide has been incorporated into RNA of
several cytosolic and mitochondrial tRNA. This modiﬁcation plays an
essential role in tRNA function and in stabilizing their secondary and
tertiary structures. Pseudouridylation is the most frequently found
modiﬁcation in tRNAs and seems to increase the protein synthesis
efﬁciency. Mutations of this gene have been identiﬁed by homozy-
gosity mapping in patients with mitochondrial myopathy, lactic
acidosis and sideroblastic anemia (MLASA) [7] (Table 1, Fig. 2). Some
patients also had mental retardation and microcephaly. The clinical
presentation can be markedly different between patients and it has
been suggested that the double localization of PUS1, and its effects on
two spatially and functionally separated translational machineries,
may account, at least in part, for the variability in the clinical
presentations. However, a relatively similar syndrome is related to
mutations of the mitochondrial tyrosyl-tRNA synthetase (YARS2, see
below) suggesting that abnormal cytosolic translation is not the only
factor involved in clinical heterogeneity of PUS1 mutations.
TRMU encodes mitochondria-speciﬁc tRNA-modifying enzyme
that is required for the 2-thio modiﬁcation of 5-taurinomethyl-2-
thiouridine tRNA-Lys on the wobble position of the anticodon. This
gene has been identiﬁed as a nuclear modiﬁer able to modulate the
phenotypic manifestation of human mitochondrial 12S rRNA muta-
tions associated with deafness. Indeed, the A1555G and C1494T
mutations, although primary factors underlying the development of
deafness, are not alone sufﬁcient to produce a deafness phenotype
[18]. Interestingly, all members of various families carrying both a
TRMU A10S replacement and the 12S rRNA mutations exhibited
prelingual profound deafness. More recently, linkage analysis and
candidate gene sequencing allowed to determine that TRMU
mutations result in acute infantile liver failure [59] (Table 1, Fig. 2).
Several of these patients died before 1 year of age but part of them
surviving the initial acute episode, showed clinical and biochemical
resolution of liver failure and had no further episodes. The
mitochondrial translation defect observed in the patients could be
related from reduced modiﬁcation of thio-modiﬁed mitochondrial
tRNAs.
3.5. Abnormal ribosomal proteins
The 55S mammalian mitochondrial ribosome consists of a small
(28S) and a large subunit (39S). The small subunit (SSU) contains a
12S rRNA and 30 proteins while the large subunit contains of a 16S
rRNA and 48 proteins [24,25]. Both the 12S and the 16S rRNAs are
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(MRP) are nuclearly encoded. This will obviously require coordinate
expression of nuclear and mitochondrial genomes. The protein:RNA
ratio in the mitochondrial ribosome is the inverse of that of its
prokaryotic counterpart and it was thought for long that the
additional and/or larger proteins of the mitochondrial ribosome
must compensate for the shortened rRNAs. However, it has been
found that the enlarged and additional proteins present in the
mitoribosome do not necessarily compensate for the missing rRNA
segments but that these proteins occupy new quaternary positions in
both subunits of the mitoribosome [43]. Whereas rRNA have catalytic
function, ribosomal proteins not only have structural but also
biological functions in translation [6].
Up till now, mutations in two mitochondrial ribosomal proteins
only have been reported [28,39]. MRPS16 mutation was found in a
patient with agenesis of the corpus callosum, muscle hypotonia and
hyperlactatemia [28]. MRPS22 mutation results in hypotonia, cardio-
myopathy and tubulopathy [39]. A recently reported MRPS22
mutation was found in a patient with brain anomalies, hypertrophic
cardiomyopathy and Cornelia de Lange-like phenotype [48] (Table 1,
Fig. 2). Both proteins were part of the SSU and their mutations not
only result in reduced amounts of the corresponding proteins but also
in a partial assembly of the SSU. Indeed another small subunit protein,
MRPS11, and the 12S rRNAwere decreased in cultured skin ﬁbroblasts
of these patients [16] whereas the large subunit was still present
despite a non-functional small subunit. Further identiﬁcation of SSU
protein mutations will indicate if other proteins are essential for SSU
assembly and probably will help in understanding the normal
assembly of the mitochondrial ribosome.
A correct assembly of the mitochondrial ribosome certainly
involves several factors but few of them are known. It has beenTable 1
Nuclear genes involved in mitochondrial translation deﬁciency in human.
Gene Protein Number of
patients
Clinical pres
tRNA-modifying enzymes
PUS1 Pseudouridine synthase 1 N4 patients Sideroblastic
TRMU tRNA 5-methylaminomethyl-2-
thiouridylate methyltransferase
7 patients Liver failure
Ribosomal proteins
MRPS16 Mitochondrial ribosomal protein S16 1 patient Agenesis of
MRPS22 Mitochondrial ribosomal protein S22 1 family Hypotonia, c
1 patient Brain anoma
cardiomyop
Aminoacyl-tRNA
synthetases
RARS2 Arginyl-tRNA synthetase 2 3 patients/
families
Pontocerebe
DARS2 Aspartyl-tRNA synthetase 2 N30 families Leukoenceph
SARS2 Seryl-tRNA synthetase 2 3 families Hyperuricem
failure
YARS2 Lysyl-tRNA synthetase 2 2 families Sideroblastic
HARS2 Histidyl-tRNA synthetase 1 family Perrault syn
sensorineura
Elongation factors
GFM1 mtEFG1 4 patients/
families
Encephalopa
TSFM mtEFTs 2 patients/
families
Encephalom
TUFM mtEFTu 1 patient Leukodystro
Termination factor
C12orf65 2 families Leigh syndro
ophthalmop
Translation activators
LRPPRC Leucine-rich PPR-motif containing
protein
55 patients Leigh Syndro
(LSFC)
TACO1 Translational activator of cytochrome c
oxidase
1 family Leigh syndroshown in yeast that Afg3/Yta10 m-AAA protease, involved in protein
quality control, also regulates ribosome assembly by controlling
proteolytic maturation of Mrpl32 protein [31]. Loss of function
mutations in the human corresponding protein, paraplegin, results
in hereditary spastic paraplegia [9].
3.6. Abnormal aminoacyl-tRNA synthetases
To initiate translation, aminoacyl-tRNA synthetases (AARSs) must
ﬁrst catalyze the ligation of speciﬁc amino acids to their cognate
tRNAs. The correct recognition of amino acids and tRNAs by these
enzymes is crucial for the ﬁdelity of protein synthesis. Whereas tRNAs
are encoded by mtDNA, AARSs are all encoded by nuclear genes,
translated in the cytosol and then imported in the mitochondria. The
mitochondria use 20 different AARSs, three of them also acting in the
cytosol (GARS, KARS, and QARS). These three enzymes are thus
essential for protein synthesis in both cellular locations [1]. Whereas
fewmutations have been reported in cytosolic AARSs, more and more
mutations in mitochondrial AARSs are now reported [1]. GARS and
YARS mutations have been reported in autosomal dominant forms of
Charcot–Marie–Tooth disease type 2D (CMT2D) and dominant
intermediate Charcot–Marie–Tooth disease (DI-CMT) respectively
[1]. However, there is no evidence for mitochondrial involvement in
these diseases. Mutations of mitochondrial AARSs result in autosomal
recessive diseases with onset in the ﬁrst months of life (Table 1,
Fig. 2).
Leukoencephalopathy with brain stem, spinal cord involvement
and lactate elevation (LBSL) is an early onset, autosomal recessive
disease characterized by cerebellar ataxia, spasticity, and variable
cognitive impairment. All patients present a speciﬁc brain magnetic
resonance imaging (MRI) as well as increased lactate at magneticentation Age at
onset
Outcome Reference
anemia+myopathy 6 months–
12 years
[7]
2–4 months Death at 3–4 months
or recovering
[59]
corpus callosum, hypotonia Neonat Death at 2–22 days
D3
[28]
ardiomyopathy Neonat Death at 2–22 days [39]
lies, hypertrophic
athy, Cornelia de Lange-like
Neonat Alive at 6 years [48]
llar hypoplasia Neonat Death before 2 years [15]
alopathy 3–15 yr [42]
ia, pulm hypertesion,renal 4 months Death at 10 months [4]
anemia+myopathy Infancy Death at 18–26 years [37]
drome (ovarian dysgenesis,
l hearing loss)
2–3 yr [33]
thy/liver failure Neonat Death at before
2 years
[3,12,47,52]
yopathy/cardiomyopathy Neonat Death at 7 weeks [46]
phy Neonat Death at 14 months [52]
me, optic atrophy,
legia
1 years Alive at 7 and
20 years
[2]
me French Canadian variant Infancy Death at 6–
69 months
[29]
me Childhood [55]
Fig. 2. The schematic steps of mitochondrial protein synthesis. The gene mutations as well as the associated clinical phenotypes are shown. (LS: Leigh syndrome).
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dysfunction. By genetic mapping and candidate gene analysis in
several unrelated sib pairs, mutations in DARS2 gene have been
identiﬁed as a recurrent cause of this syndrome [42]. DARS2 encodes
the mitochondrial aspartyl-tRNA synthetase. The most common
mutation is a splice-site mutation in intron 2 that results in the
deletion of exon 3, a frameshift (R76SfsX5), and the premature
termination of the protein. Whereas the enzyme activity of the
mutant proteins expressed in Escherichia coli were consistently
reduced, no OXPHOS or mitochondrial protein synthesis deﬁciency
could be detected in patients' cells. Numerous patients with a similar
clinical presentation and MRI features have then been reported
[21,26].
Pontocerebellar hypoplasia (PCH) represents a group of autosomal
recessive neurodegenerative disorders with prenatal onset. Six sub-
types of pontocerebellar hypoplasia have been identiﬁed each of them
being characterized by speciﬁc additional features. PCH6 is charac-
terized by severe infantile encephalopathy, cerebral atrophy and
multiple OXPHOS deﬁciency and is associated with RARS2 mutations
[15]. RARS2 encodes the mitochondrial arginyl-tRNA synthetase and
the ﬁrst mutation was identiﬁed by homozygosity mapping and gene
sequencing. This splicing mutation resulted in reduction of the
amount of the mitochondrial tRNAArg suggesting that this uncharged
tRNA become unstable [15]. Additional patients were subsequently
reported. MRI ﬁndings were similar to those previously published, the
patients presented high levels of CSF lactate but OXPHOS enzymes
were variably affected [30,35]. Finally, RARS2 mutations represent a
rare cause of PCH as only two patients from a large series of 169 PCH
patients presented RARS2 mutations [30].
YARS2 encodes the tyrosyl-tRNA synthetase and was identiﬁed as
the disease causing gene in two families with mitochondrial
myopathy, lactic acidosis and sideroblastic anemia (MLASA). The
clinical presentation of the patients is highly similar to those with
PUS1mutations but onset of symptomswas at an earlier age for YARS2mutations. The same homozygous mutation (F52L) was found in two
unrelated consanguineous families of Lebanese origin [37]. The
patients presented multiple OXPHOS deﬁciency in muscle and
deﬁcient mitochondrial protein synthesis in myotubes but not in
cultured skin ﬁbroblasts. Finally, aminoacylation activity of the
mitochondrial tyrosyl-tRNA synthetase showed a 2-fold decrease
compared to controls [37].
The HUPRA syndrome is a recently described multisystem fatal
mitochondrial disease characterized by HyperUricemia, Pulmonary
hypertension, Renal failure and Alkalosis) [4]. The onset of the
disease is between 4 and 7 months of age and the patients also
present high blood and CSF lactate suggesting a mitochondrial
dysfunction. Indeed immunohistochemical staining in muscle biopsy
showed COX deﬁciency and enzyme assays revealed multiple
OXPHOS deﬁciency. Homozygostity mapping in two apparently
unrelated families revealed the same SARS2 mutation. The mito-
chondrial seryl-tRNA synthetase (SARS2) provides serine aminoa-
cylation to two mitochondrial tRNAs (tRNASer AGY and tRNASer UCN).
The D390G SARS2 mutation resulted in a 10–20% residual amount of
tRNASer AGY whereas tRNASer UCN amount was in the normal range
suggesting that the mutation impairs the ability of the enzyme to
acylate tRNASer AGY and that uncharged tRNA undergoes degradation
[4].
Perrault syndrome is a clinically and genetically heterogeneous
recessive disease characterized by ovarian digenesis and sensorineu-
ral hearing loss. Genetic mapping in a large non-consanguineous
family allowed to show that the disease is related to mutations in
HARS2 gene encoding the mitochondrial histidyl-tRNA synthetase
[33]. HARS2 mutations were found in only 1/10 pedigree. In one
additional family Perrault syndrome is caused by mutations in
HSD17B4 encoding the 17β-hydroxysteroid dehydrogenase type 4,
an enzyme involved in peroxisomal fatty acid beta-oxidation [33].
Why mutations in these different genes result in Perrault syndrome
has still to be investigated.
1203A. Rötig / Biochimica et Biophysica Acta 1807 (2011) 1198–12053.7. Abnormal elongation factor
The mitochondrial translation elongation consists of sequential
addition of amino acids to the growing polypeptide chain directed by
mRNA codons. Our knowledge of mitochondrial translation elonga-
tion is essentially derived from studies in bacteria. This process
involves in mammals three elongation factors mtEFTu, mtEFTs and
mtEFG. mtEFTu associates with all aminoacyl-tRNA substrates thus
protecting them from hydrolysis. The aminoacyl-tRNA is then
delivered to the aminoacyl-tRNA site (A site) of the ribosome as a
ternary complex with mtEFTu and GTP for decoding of mRNA by
codon–anticodon interactions in the small ribosomal subunit. GTP
hydrolysis on mtEFTu then results in release of mtEFTu·GDP. mtEFTs,
a nucleotide exchange protein converts mtEFTu·GDP in active
mtEFTu·GTP. The peptide from the peptidyl-tRNA in the P-site of
the ribosome moves into the peptidyl transferase center in the large
subunit for peptide bound formation. In prokaryotes, mtEFG catalyzes
the translocation step in which the deacylated tRNA in the P-site is
moved to the exit site (E-site). However, several ﬁndings suggest that
the E-site is absent from mitochondrial ribosome. Subsequently, the
ribosomemoves 3 nucleotides relative to the mRNA. The cycle repeats
with a new ternary complex entering the A-site [50]. Protein synthesis
deﬁciencies associated with the three mitochondrial elongation
factors mtEFTu, mtEFTs and mtEFG have been described. Human
mitochondria have two forms of mtEFG factors, mtEFG1 and mtEFG2,
that present 35% of identity but mutations in mtEFG1 only have been
identiﬁed. mtEFG1 has been demonstrated to speciﬁcally catalyze
translocation, whereas mtEFG2 mediates ribosome recycling and
renamed RRF2mt [51]. All patients with mtEFG1 mutations present a
severe disease, sometimes with prenatal manifestation such as
intrauterine growth retardation, which results in a premature death
usually before 2 years of age (Table 1, Fig. 2). Mutations of these genes
are relatively rare as systematic studies performed on different series
of patients with multiple OXPHOS deﬁciencies allowed to identify
roughly less than 8/100 patients with translation elongation factors
mutations [3,12,23,46,47,52]. These translation elongation factor
deﬁciencies resulted in globally decreased mitochondrial translation
in cultured skin ﬁbroblasts of patients, some proteins being more
severely affected than others. Moreover additional bands which could
not be attributed to a speciﬁc mtDNA encoded protein are sometimes
observed. Mutations of GFM1 gene, encoding mtEFG1, result in either
in liver failure [3,12] or encephalopathy [47,52]. Only one patient with
TUFM (encoding mtEFTu) mutation has been hitherto reported [52].
The patient had severe infantile macrocystic leukodystrophy with
micropolygyria. He also had acute metabolic acidosis, psychomotor
regression and axial hypotonia. Surprisingly the same TSFM (encoding
EFTs) mutation has been found in two unrelated kindred presenting
two distinct syndromes (fatal mitochondrial encephalomyopathy for
the ﬁrst patient and hypertrophic cardiomyopathy for the second)
[46].
3.8. C12orf65
Several factors are involved in mitochondrial translation termina-
tion: the release factor mtRF1a/mtRF1L and the two ribosome
recycling factors mtRRF (encoded by MRRF gene) and mtRRF2
(previously named mtEFG2). It should be hypothesized that other
yet unknown factors also act as translation termination factors. Indeed,
C12orf65 contains the GGQ motif that characterizes the class I release
factors (mtRF1, Ict1 [36]) at the active site of the protein that catalyzes
the hydrolysis of the ester bond. The precise function of C12orf65
protein has still to be characterized but mutations of this gene were
found in patients from two different families with Leigh syndrome,
optic atrophy and ophthalmoplegia [2] (Table 1, Fig. 2). Fibroblasts of
the patients presentedOXPHOS deﬁciency, abnormal BP-PAGE pattern
and deﬁcient mitochondrial mRNA translation. The two unrelatedpatients presented two different homozygous 1 bp deletions. Both
mutations predict the same premature stop codon at position 84 of the
amino acid sequence. Overexpression of Ict1 resulted in partial
increase of COX activity in a patient's ﬁbroblasts suggesting that
C12orf65 and Ict1 may have similar and overlapping functions.
3.9. Translational activators
The mechanisms of mitochondrial protein synthesis regulation are
poorly understood in mammals whereas several gene-speciﬁc
translation activation factors are required in yeast. These yeast
translation activators bind to the 5′ UTR sequences of the mRNAs.
Mammalian mitochondrial mRNAs lack 5′ UTR and until recently no
translation factors were known suggesting that translation regulation
involves other mechanisms than in yeast. Identiﬁcation of some
disease causing genes in patients will certainly allow to progressively
identify these yet unknown factors (Table 1, Fig. 2).
The LRPPRC gene is the causative gene for the Leigh Syndrome
French Canadian variant (LSFC) [29]. LRPPRC is a distant homolog of
the yeast translational activator Pet309. The protein is supposed to be
involved in the stabilization of the mRNAs for COXI and COXIII in
mammals without affecting their translation [57].
A speciﬁc defect in the synthesis of COXI subunit encoded by
mtDNA has been found in a family of late-onset Leigh syndrome and
isolated COX deﬁciency. Genetic mapping and chromosome transfer
in a patient's ﬁbroblasts allowed to show that this deﬁciency resulted
from mutation in a new gene, TACO1 (translational activator of COXI)
[55]. Whereas the exact function of TACO1 is not known it has been
shown to localize into the mitochondria and is supposed to either
function as a multimer or in a complex with another protein(s).
4. Genetic screening of mitochondrial protein synthesis deﬁciency
The identiﬁcation of genetic defects of mitochondrial protein
synthesis increases rapidly as well as the clinical heterogeneity
associated with these deﬁciencies. The large number of patients with
multiple OXPHOS deﬁciency possibly due to protein synthesis defects
as well as the large number of known and possibly unknown genes
involved in translation hampers an easy and simple investigation of
the patients. Several clinical and laboratory investigations can help to
diagnose protein synthesis deﬁciency but none of them is usually
sufﬁcient for a rapid diagnosis.
The clinical presentation of patients is extremely heterogeneous
even in a speciﬁc subgroup of proteins such as aminoacyl-tRNA
synthetases or ribosomal proteins for example. Few patients with the
same genemutations have been described inmost cases hampering to
establish genotype–phenotype correlations. Moreover, the same
clinical features can be related to two different gene mutations
(myopathy and sideroblastic anemia related to PUS1 [7] or YARS2 [37]
mutations) and one speciﬁc EFTs mutation can result in at least two
distinct phenotypes [46].
Brain MRI images of patients with neurological disease reveal
common features such as severe sus-tentorial atrophy and pontine
atrophy of the brainstem. This pattern should perhaps be regarded as
a suggestive/distinctive feature in mitochondrial protein synthesis
defects. Whether these features are speciﬁc to translation deﬁciency
has still to be determined. Brain MRI is particularly instrumental for
the diagnosis of DARS2 mutations as all patients presented leukoen-
cephalopathy with brain stem, spinal cord involvement and lactate
elevation (LBSL).
A multiple OXPHOS deﬁciency sparing complex II is observed in
most patients. However, some patients with GFM1 mutations can
present isolated complex IV deﬁciency in muscle or can result in
multiple OXPHOS deﬁciency in ﬁbroblasts but not in muscle [47].
Patients with DARS2 mutations do not express any deﬁciency in
available tissues such as muscle and ﬁbroblasts [42].
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OXPHOS assembly pattern showing low fully assembled complexes
I, IV and V. Therefore, BN-PAGE analysis represents a relatively reliable
and easy diagnostic tool for these deﬁciencies. However, BN-PAGE
analysis has not been documented in all translation deﬁciencies
hampering to establish if it should be the best diagnosis tool.
Obviously, mitochondrial protein synthesis assay involving [35S]-
methionine pulse-chased labeling should represent the gold standard
for diagnosis of these defects. It is however relatively expansive and
time consuming hampering its use as an easy diagnosis tool. However,
this deﬁciency is sometimes tissue speciﬁc as myoblasts but not
ﬁbroblasts of patients with YARS2 mutations display decreased
mitochondrial protein synthesis [37].
Finally, due to the short size of the families with protein synthesis
deﬁciencies genetic mapping often cannot be applied.
5. Conclusion
Mitochondrial protein synthesis problemsarebecomingan important
cause of OXPHOS dysfunction. The ﬁrst mitochondrial MELAS mutation
has beendescribedmore than20 years ago [17] and theﬁrst nuclear gene
mutation (PUS1) in 2004 [7]. Then 15 additional nuclear gene mutations
have been reported. New techniques for gene identiﬁcation, such as
exome sequencingwill rapidly allow to expand the list of genes involved
in mitochondrial diseases and especially in the case of abnormal
translation. In addition it could also help to determine the modiﬁer
genes that could partly account for the clinical variability that is a
hallmark of mitochondrial disorders.
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